Condition: Prostate Cancer · Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Multicenter, open-label, parallel-group, phase II randomized study in patients with oligometastatic prostate cancer with 1-3 asymptomatic metastases of the soft tissue or bone. Eligible patients will be randomized at 1:1 ratio to Stereotactic Radiotherapy followed by Lu-PSMA (arm A) or Stereotactic Radiotherapy (arm B)
This description comes directly from the study's public registry record.
Oriana Nanni · +390543739100 · cc.ubsc@irst.emr.it
Bernadette Vertogen · +390544286058 · cc.ubsc@irst.emr.it
Always discuss trial participation with your own doctor first.
| UO Medicina Nucleare, AUSL della Romagna | Cesena, FC, Italy | Recruiting |
| UO Medicina Nucleare, IRCCS IRST | Meldola, FC, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05893381